Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 50

recruiting
3 987
countries
28
conditions
2 109

1 221 trials match your criteria

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Study on the Effectiveness of Abemaciclib, Inavolisib, and Giredestrant in Patients with Early HR-positive/HER2-negative Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Chronic kidney disease

Not yet recruiting

Study on the Effects of Finerenone, Dapagliflozin, and Ambrisentan in Patients with Chronic Kidney Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ambrisentan

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Tuberculosis

Not yet recruiting

Study on the Safety and Tolerability of Higher Dose Rifampicin for Tuberculosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rifampicin

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.